Pam Palmer: No, and that’s the beauty of nafamostat is that it is as simple to initiate as heparins. And that’s why heparins being used for so long, it’s very simple. Citrate avoids the bleeding risk that heparin has. But it’s got so many other risks, and it’s very difficult to run for these sites. And so to simplify the treatment, get back something as simple as heparin, which is what a nafamostat would do with potentially much less bleeding, and some of the other problems that happened like heparin, like Heparin-induced thrombocytopenia or heparin resistance. It’s just — it really is going to make it hopefully be a anticoagulant that is easy to use in all the patients, and it’s great for the nurses and they will be happy to adopt it.
James Molloy: Okay. Maybe last question for me then I’ll hop back in the queue. Looking down the road, is there other opportunities that you guys are seeing beyond obviously the pre-filled syringes to complement nafamostat and your
Vince Angotti: Yeah. So first of all, we’ll be evaluating the potential development opportunities with LTX-608, where they’ve already been proven ex-US. Pam, some of those disease states again are —
Pam Palmer: Yeah. Acute pancreatitis, disseminated intravascular coagulation —
Vince Angotti: Are actually approved indications ex-US, and there’s other potential applications as well. So again, I’ll reiterate that LTX-608 really is a pipeline and a product for us. And our goal, of course, in the short term is to get it across the finish line as efficiently as we can over the course of this next year. Beyond that, we are in business development discussions. We have business development discussions, in particular, ex-US for some parties that are interested in Niyad. So we’ll continue to evaluate those opportunities moving forward, but want to be sure that we absolutely maximize the value of this asset for our shareholders.
James Molloy: All right. Thank you for taking the questions.
Vince Angotti: Thank you, Jim.
Operator: This will conclude our question-and-answer session. I’ll turn the conference back over to Vince for any closing remarks.
Vince Angotti: Thank you, operator, and thank you all for joining us today and for your continued support of AcelRx. We remain focused on driving long-term shareholder value absolutely with targeted investment and our late-stage development high-value assets. Please feel free to contact us after the call if you have any additional questions, and we look forward to sharing our future, in particular, near future developments. Thank you.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
